Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers

Expert Opinion on Investigational Drugs

Volumn 22, Issue 3, 2013, Pages 341-356

  Desai, Monica Dandona ^a   Saroya, Bikramajit Singh ^a   Lockhart, Albert Craig ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Cetuximab; ErbB (HER) family; Gastrointestinal cancers; Monoclonal antibodies; Trastuzumab; Tyrosine kinase inhibitors

Indexed keywords

AFATINIB; AMG 888; BEVACIZUMAB; CANERTINIB; CAPECITABINE; CETUXIMAB; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIRUBICIN; ERLOTINIB; ERTUMAXOMAB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; MATUZUMAB; NERATINIB; NIMOTUZUMAB; OXALIPLATIN; PANITUMUMAB; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG;

CELL MIGRATION; CELL SURVIVAL; COLORECTAL CANCER; DOWNSTREAM PROCESSING; ESOPHAGUS CANCER; HEPATOBILIARY SYSTEM CANCER; HUMAN; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; REVIEW; TUMOR GROWTH;

CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; GASTROINTESTINAL NEOPLASMS; HUMANS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84873668603     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.761972     Document Type: Review

References (129)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29
2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
3. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46
4. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91
5. Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-8
6. Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010;CD004064
7. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38
8. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007;37(Suppl 2):S88-94
9. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91
10. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
11. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25
12. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90
13. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37(Suppl 4):S3-8
14. Perez-Soler R. HER1/EGFR targeting: refining the strategy. Oncologist 2004;9:58-67
15. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232
16. Burgess AW, Cho HS, Eigenbrot C, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003;12:541-52
17. Cohen S, Carpenter G, King L Jr. Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem 1980;255:4834-42
18. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16
19. Hanawa M, Suzuki S, Dobashi Y, et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 2006;118:1173-80
20. Itakura Y, Sasano H, Shiga C, et al. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994;74:795-804
21. Wang KL, Wu TT, Choi IS, et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 2007;109:658-67
22. Kim MA, Lee HS, Lee HE, et al. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 2008;52:738-46
23. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6
24. Ito Y, Takeda T, Sakon M, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 2001;84:1377-83
25. McKay JA, Murray LJ, Curran S, et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 2002;38:2258-64
26. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
27. Galizia G, Lieto E, De Vita F, et al. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 2007;26:3654-60
28. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-14
29. Okines A, Cunningham D, Chau I. Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol 2011;8:492-503
30. Reddy D, Wainberg ZA. Targeted therapies for metastatic esophagogastric cancer. Curr Treat Options Oncol 2011;12:46-60
31. Enzinger PC, Burtness B, Hollis D, et al. CALGB 80403/ECOG 1206: a randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. J Clin Oncol 2010;28:15s
32. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009;20:1667-73
33. Asnacios A, Fartoux L, Romano O, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 2008;112:2733-9
34. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 2004;22:2610-16
35. Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010;28:3605-10
36. Louafi S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007;109:1384-90
37. Sanoff HK, Bernard S, Goldberg RM, et al. Phase II study of Capecitabine, Oxaliplatin, and Cetuximab for advanced hepatocellular carcinoma. Gastrointest Cancer Res 2011;4:78-83
38. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17
39. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71
40. Berardi R, Onofri A, Pistelli M, et al. Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer. Core Evid 2010;5:61-76
41. Okines AF, Ashley SE, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol 2010;28:3945-50
42. Waddelll TS, Chau I, Brarbachano Y, et al. A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). J Clin Oncol 2012;30(Suppl)):abstract LBA40000
43. Kim GP, Foster NR, Salim M, et al. Randomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE) versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic pancreatic adenocarcinoma. J Clin Oncol 2011;29(Suppl):abstract 4030
44. Sun W, Mykulowycz K, Teitelbaum UR, et al. Panitumumab, gemcitabine, and irinotecan in patients with advanced or metastatic cholangiocarcinoma: a phase II study. J Clin Oncol 2010;28(Suppl):abstract TPS214
45. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64
46. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27:672-80
47. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-705
48. Vanhoefer U, Tewes M, Rojo F, et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004;22:175-84
49. Rao S, Starling N, Cunningham D, et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol 2010;21:2213-19
50. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006;24:4922-7
51. Wainberg ZA, Lin LS, DiCarlo B, et al. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br J Cancer 2011;105:760-5
52. Thomas MB, Chadha R, Glover K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007;110:1059-67
53. Chiorean EG, Ramasubbaiah R, Yu M, et al. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: hoosier Oncology Group GI06-101. Oncologist 2012;17:13
54. Philip PA, Mahoney MR, Holen KD, et al. Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. Cancer 2012;118:2424-30
55. Kozuch P, Malamud S, Wasserman C, et al. Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer. Clin Colorectal Cancer 2009;8:38-42
56. Messersmith WA, Jimeno A, Jacene H, et al. Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clin Colorectal Cancer 2010;9:297-304
57. Meyerhardt JA, Stuart K, Fuchs CS, et al. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Ann Oncol 2007;18:1185-9
58. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006;24:1612-19
59. Ferry DR, Anderson M, Beddard K, et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 2007;13:5869-75
60. Ferry DR. Phase III multi-centre, randomised, double-blind, placebo-controlled parallel arm of geftinib versus placebo in esophgeal cancer progressing after chemotherapy on behalf of the COG (Cancer Oesophagus Gefitinib) Collaborative Group [abstract LBA20-PR]. European Society of Medical Oncology (ESMO) 2012 Congress; Vienna, Austria; 2012
61. Doi T, Koizumi W, Siena S, et al. Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer. Proc Am Soc Clin Oncol 2003;22:abstract 1036
62. Phase II Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma. Available from: ClinicalTrials.gov, http://clinicaltrials. gov/show/NCT00177242 [Accessed 4 October 2012]
63. O'Dwyer PJ, Giantonio BJ, Levy DE, et al. Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern cooperative oncology group's study E1203. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24:abstract No. 4143
64. Rothenberg ML, LaFleur B, Levy DE, et al. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 2005;23:9265-74
65. Fukushige S, Matsubara K, Yoshida M, et al. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 1986;6:955-8
66. Rowinsky EK. Signal events: cell signal transduction and its inhibition in cancer. Oncologist 2003;8(Suppl 3):5-17
67. Kraus AC, Ferber I, Bachmann SO, et al. In vitro chemo-and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene 2002;21:8683-95
68. Sakai K, Mori S, Kawamoto T, et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst 1986;77:1047-52
69. Ooi A, Takehana T, Li X, et al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004;17:895-904
70. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97
71. Xian ZH, Zhang SH, Cong WM, et al. Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma. J Clin Pathol 2005;58:500-3
72. Zender L, Villanueva A, Tovar V, et al. Cancer gene discovery in hepatocellular carcinoma. J Hepatol 2010;52:921-9
73. Safran H, Steinhoff M, Mangray S, et al. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 2001;24:496-9
74. Harder J, Ihorst G, Heinemann V, et al. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer 2012;106:1033-8
75. Safran H, Iannitti D, Ramanathan R, et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 2004;22:706-12
76. Cartwright TH, Cohn A, Varkey JA, et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002;20:160-4
77. Ramanathan RK, Hwang JJ, Zamboni WC, et al. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest 2004;22:858-65
78. Blackwell KL, Miles D, Gianni L, et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. J Clin Oncol 2012;30(Suppl):abstract LBA1
79. A randomized, multicenter, adaptive phase II/III study to evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) versus taxane (Docetaxel Or Paclitaxel) in patients with previously treated locally advanced or metastatic Her2-positive gastric cancer, including adenocarcinoma of the gastroesophageal junction. Available from: http://clinicaltrials.gov/ct2/show/NCT01641939 [Accessed 6 October 2012]
80. Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-19
81. Keating GM. Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer. Drugs 2012;72:353-60
82. Yamashita-Kashima Y, Iijima S, Yorozu K, et al. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res 2011;17:5060-70
83. Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005;23:2534-43
84. Phase II study of pertuzumab and erlotinib for refractory pancreatic adenocarcinoma. Available from: Clinicaltrials.gov, http://clinicaltrials.gov/ ct2/show/NCT01108458 [Accessed 30 November 2012]
85. A study of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2-positive advanced gastric cancer. Available from: ClinicalTrials.gov, http://clinicaltrials. gov/ct2/show/NCT01461057 [Accessed 6 October 2012]
86. A phase I/II trial of pertuzumab in combination with cetuximab in cetuximab-refractory metastatic colorectal cancer. Available from: ClinicalTrials.gov, http://clinicaltrials.gov/ct2/show/NCT00551421 [Accessed 6 October 2012]
87. mFOLFIRI combine with nimotuzumab second line chemotherapy for squamous-cell carcinoma of the Esophagus. Available from: Clinicaltrials. gov, http://clinicaltrials.gov/ct2/show/results/NCT01486992? term= NCT01486992&rank=1 [Accessed 6 October 2012]
88. Nimotuzumab in combination with chemoradiation for local advanced esophageal squamous cell carcinoma. Available from: ClinicalTrials.gov, http://clinicaltrials.gov/ct2/show/NCT01232374 [Accessed 6 October 2012]
89. Combination of nimotuzumab, capecitabine and radiotherapy for inoperable or recurrent gastric cancer. Available from: ClinicalTrials.gov, http://clinicaltrials.gov/show/NCT01180166 [Accessed 6 October 2012]
90. Nimotuzumab in adults with pancreatic cancer. Available from: Clinicaltrials.gov, http://www.clinicaltrials.gov/ct2/show/NCT00561990 [Accessed 6 October 2012]
91. Strumberg D, Schultheis B, Scheulen ME, et al. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs 2012;30:1138-43
92. Open label, dose escalating study with ertumaxomab in patients with HER-2/Neu expressing advanced solid tumors. Available from: Clinicaltrials.gov, http://clinicaltrials.gov/ct2/show/NCT01569412 [Accessed 6 October 2012]
93. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43
94. Wainberg ZA, Anghel A, Desai AJ, et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 2010;16:1509-19
95. Roth A, Moehler MH, Mauer M, et al. Lapatinib in combination with ECF/x in EGFR1 or HER2-overexpressing firstline metastatic gastric cancer (GC): a phase II randomized placebo controlled trial (EORTC 40071). J Clin Oncol 2010;28(Suppl):abstract TPS205
96. Satoh T, Bang Y, Wang J, et al. Interim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer. J Clin Oncol 2010;28(Suppl):abstract 4057
97. A Phase III study for ErbB2 positive advanced or metastatic gastric, esophageal, or gastroesophageal junction adenocarcinoma treated with capecitabine plus oxaliplatin with or without lapatinib. Available from: Clinicaltrials. gov, http://clinicaltrials.gov/ct2/show/NCT00680901 [[Accessed 7 October 2012]
98. Singla S, Pippin JA, Drebin JA. Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer. Oncol Rep 2012;28(6):2211-16
99. Safran H, Miner T, Bahary N, et al. Lapatinib and gemcitabine for metastatic pancreatic cancer: a phase II study. J Clin Oncol 2009;27:e15653
100. Frank D, Jumonville A, Loconte NK, et al. A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: a Wisconsin Oncology Network study. J Gastrointest Oncol 2012;3:90-6
101. A phase II study of Afatinib (BIBW 2992) in patients with advanced HER2-positive Trastuzumab-refractory advanced Esophagogastric cancer. Available from: ClinicalTrials.gov, http://clinicaltrials.gov/ct2/show/NCT01522768 [Accessed 7 October 2012]
102. An open label, partially randomised phase II study to investigate the efficacy and safety of BIBW 2992 in patients with metastatic colorectal cancer who never received prior anti-EGFR (Epidermal Growth Factor Receptor) treatment. Available from: ClinicalTrials. gov, http://clinicaltrials.gov/ct2/show/ NCT01152437 [Accessed 7 October 2012]
103. Ioannou N, Dalgleish AG, Seddon AM, et al. Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. Br J Cancer 2011;105:1554-62
104. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 2007;97:453-7
105. Soltoff SP, Carraway KL III, Prigent SA, et al. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 1994;14:3550-8
106. Reschke M, Mihic-Probst D, van der Horst EH, et al. HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res 2008;14:5188-97
107. Beji A, Horst D, Engel J, et al. Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer. Clin Cancer Res 2012;18:956-68
108. Amin DN, Campbell MR, Moasser MM. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol 2010;21:944-50
109. Garrett JT, Olivares MG, Rinehart C, et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA 2011;108:5021-6
110. Berlin J, Keedy VL, Janne PA, et al. A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol 2011;29(Suppl):abstract 3026
111. Schoeberl B, Faber AC, Li D, et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010;70:2485-94
112. Sequist LV, Harb WA, Modiano M, et al. A phase I/II trial of MM-121 in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29(Suppl):abstract TPS215
113. A Phase 1 study of MM-121 in combination with cetuximab and irinotecan in patients with advanced cancers. Available from: ClinicalTrials. gov, http://clinicaltrials.gov/ct2/show/NCT01451632 [Accessed 8 October 2012]
114. Kamath AV, Lu D, Gupta P, et al. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. Cancer Chemother Pharmacol 2012;69:1063-9
115. Nam HJ, Ching KA, Kan J, et al. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer. Mol Cancer Ther 2012;11:439-51
116. Oh DY, Lee KW, Cho JY, et al. A phase II open-label trial of dacomitinib monotherapy in patients with HER2-positive advanced gastric cancer after failure of at least one prior chemotherapy regimen. J Clin Oncol 2012;30(Suppl 4):abstract 54
117. Dechant M, Weisner W, Berger S, et al. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 2008;68:4998-5003
118. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000;60:1383-7
119. Hopper-Borge EA, Nasto RE, Ratushny V, et al. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets 2009;13:339-62
120. Castillo J, Erroba E, Perugorria MJ, et al. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res 2006;66:6129-38
121. Mimura K, Kono K, Hanawa M, et al. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 2005;92:1253-60
122. Wei Q, Chen L, Sheng L, et al. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol 2007;31:493-9
123. Xu S, Kitayama J, Yamashita H, et al. Nuclear translocation of HER-4/c-erbB-4 is significantly correlated with prognosis of esophageal squamous cell carcinoma. J Surg Oncol 2008;97:44-50
124. Reichelt U, Duesedau P, Tsourlakis M, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007;20:120-9
125. Begnami MD, Fukuda E, Fregnani JH, et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 2011;29:3030-6
126. Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273-8
127. Tobita K, Kijima H, Dowaki S, et al. Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int J Mol Med 2003;11:305-9
128. Hirakawa T, Nakata B, Amano R, et al. HER3 overexpression as an independent indicator of poor prognosis for patients with curatively resected pancreatic cancer. Oncology 2011;81:192-8
129. Kountourakis P, Pavlakis K, Psyrri A, et al. Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 2006;6:46